Seeking Alpha
17 Jun 2026, 18:43 UTC · 3h ago
Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
17 Jun 2026, 18:43 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
RAMP 205 phase 1b/2a results showed an 86% overall survival at 6 months and 52% confirmed objective response rate in 1st-line metastatic PDAC. — Strong early-stage efficacy data in a difficult-to-treat cancer (pancreatic) significantly increases the probability of successful drug development.
+0.80Verastem is advancing three phase 2 registration-directed studies for VS-7375 targeting PDAC, NSCLC, and CRC. — Moving into registration-directed phase 2 trials puts the company closer to potential FDA approval and commercialization.
+0.60Key data readouts from the TARGET-D 101 phase 1/2 study are expected in 2026. — Provides a future catalyst, but the long time horizon (2026) reduces the immediate price impact.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Maintained Buy rating due to positive early-stage clinical data and upcoming study catalysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
10h ago
